These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29567476)

  • 1. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
    Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
    Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
    Cai W; Ni W; Jin Y; Li Y
    Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
    Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
    Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
    Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
    Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
    Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
    Zhang G; Zhu Q; Fu G; Hou J; Hu X; Cao J; Peng W; Wang X; Chen F; Cui H
    Br J Cancer; 2019 Dec; 121(12):1069-1078. PubMed ID: 31740732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
    Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
    J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
    Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
    Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
    Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
    Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
    Niu L; Gao Z; Cui Y; Yang X; Li H
    Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
    Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
    Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
    Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
    Xiao Z; Li M; Zhang X; Rong X; Xu H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
    Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
    Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMC2 knockdown inhibits malignant progression of lung adenocarcinoma by upregulating BTG2 expression.
    He Y; Wang Y; Luo Z; Zhang X; Bai H; Wang J
    Cell Signal; 2024 Aug; 120():111216. PubMed ID: 38729325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma.
    Zhan P; Xi GM; Zhang B; Wu Y; Liu HB; Liu YF; Xu WJ; Zhu Q; Cai F; Zhou ZJ; Miu YY; Wang XX; Jin JJ; Li Q; Lv TF; Song Y
    J Cell Mol Med; 2017 Apr; 21(4):665-676. PubMed ID: 27862966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TRIP13 Enhances Radioresistance of Lung Adenocarcinoma Cells 
through the Homologous Recombination Pathway].
    Ge S; Gu R; Yang X; Xu C; Wang S; Zhu G
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):1-12. PubMed ID: 38296621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.
    Yu DC; Chen XY; Zhou HY; Yu DQ; Yu XL; Hu YC; Zhang RH; Zhang XB; Zhang K; Lin MQ; Gao XD; Guo TW
    Mol Biol Rep; 2022 Apr; 49(4):3055-3064. PubMed ID: 35032258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.